id	sid	tid	token	lemma	pos
dpc-4512	1	1	dermatology	dermatology	NOUN
dpc-4512	1	2	:	:	PUNCT
dpc-4512	1	3	practical	practical	ADJ
dpc-4512	1	4	and	and	CCONJ
dpc-4512	1	5	conceptual	conceptual	ADJ
dpc-4512	1	6	research	research	NOUN
dpc-4512	1	7	letter	letter	NOUN
dpc-4512	2	1	|	|	ADV
dpc-4512	2	2	dermatol	dermatol	ADJ
dpc-4512	2	3	pract	pract	NOUN
dpc-4512	2	4	concept	concept	NOUN
dpc-4512	2	5	.	.	PUNCT
dpc-4512	3	1	2024;14(4):e2024252	2024;14(4):e2024252	NUM
dpc-4512	3	2	1	1	NUM
dpc-4512	3	3	omalizumab	omalizumab	NOUN
dpc-4512	3	4	in	in	ADP
dpc-4512	3	5	the	the	DET
dpc-4512	3	6	treatment	treatment	NOUN
dpc-4512	3	7	of	of	ADP
dpc-4512	3	8	refractory	refractory	NOUN
dpc-4512	3	9	urticarial	urticarial	NOUN
dpc-4512	3	10	vasculitis	vasculitis	PROPN
dpc-4512	3	11	triggered	trigger	VERB
dpc-4512	3	12	by	by	ADP
dpc-4512	3	13	sars	sar	NOUN
dpc-4512	3	14	-	-	PUNCT
dpc-4512	3	15	cov-2	cov-2	PART
dpc-4512	3	16	infection	infection	NOUN
dpc-4512	3	17	:	:	PUNCT
dpc-4512	3	18	a	a	DET
dpc-4512	3	19	pediatric	pediatric	ADJ
dpc-4512	3	20	case	case	NOUN
dpc-4512	3	21	report	report	NOUN
dpc-4512	3	22	yusuf	yusuf	PROPN
dpc-4512	3	23	can	can	AUX
dpc-4512	3	24	edek1	edek1	PROPN
dpc-4512	3	25	,	,	PUNCT
dpc-4512	3	26	ecem	ecem	PROPN
dpc-4512	3	27	ertürk1	ertürk1	PROPN
dpc-4512	3	28	,	,	PUNCT
dpc-4512	3	29	esra	esra	PROPN
dpc-4512	3	30	adışen1	adışen1	PROPN
dpc-4512	4	1	1	1	NUM
dpc-4512	4	2	department	department	NOUN
dpc-4512	4	3	of	of	ADP
dpc-4512	4	4	dermatology	dermatology	NOUN
dpc-4512	4	5	,	,	PUNCT
dpc-4512	4	6	gazi	gazi	PROPN
dpc-4512	4	7	university	university	PROPN
dpc-4512	4	8	faculty	faculty	NOUN
dpc-4512	4	9	of	of	ADP
dpc-4512	4	10	medicine	medicine	NOUN
dpc-4512	4	11	,	,	PUNCT
dpc-4512	4	12	ankara	ankara	PROPN
dpc-4512	4	13	,	,	PUNCT
dpc-4512	4	14	turkey	turkey	PROPN
dpc-4512	4	15	key	key	ADJ
dpc-4512	4	16	words	word	NOUN
dpc-4512	4	17	:	:	PUNCT
dpc-4512	4	18	covid-19	covid-19	PROPN
dpc-4512	4	19	,	,	PUNCT
dpc-4512	4	20	omalizumab	omalizumab	NOUN
dpc-4512	4	21	,	,	PUNCT
dpc-4512	4	22	urticarial	urticarial	ADJ
dpc-4512	4	23	vasculitis	vasculitis	PROPN
dpc-4512	4	24	citation	citation	NOUN
dpc-4512	4	25	:	:	PUNCT
dpc-4512	4	26	edek	edek	PROPN
dpc-4512	4	27	yc	yc	NOUN
dpc-4512	4	28	,	,	PUNCT
dpc-4512	4	29	ertürk	ertürk	NOUN
dpc-4512	4	30	e	e	NOUN
dpc-4512	4	31	,	,	PUNCT
dpc-4512	4	32	adışen	adışen	PROPN
dpc-4512	4	33	e.	e.	PROPN
dpc-4512	4	34	omalizumab	omalizumab	PROPN
dpc-4512	4	35	in	in	ADP
dpc-4512	4	36	the	the	DET
dpc-4512	4	37	treatment	treatment	NOUN
dpc-4512	4	38	of	of	ADP
dpc-4512	4	39	refractory	refractory	NOUN
dpc-4512	4	40	urticarial	urticarial	NOUN
dpc-4512	4	41	vasculitis	vasculitis	PROPN
dpc-4512	4	42	triggered	trigger	VERB
dpc-4512	4	43	by	by	ADP
dpc-4512	4	44	sars	sar	NOUN
dpc-4512	4	45	-	-	PUNCT
dpc-4512	4	46	cov-2	cov-2	PART
dpc-4512	4	47	infection	infection	NOUN
dpc-4512	4	48	:	:	PUNCT
dpc-4512	4	49	a	a	DET
dpc-4512	4	50	pediatric	pediatric	ADJ
dpc-4512	4	51	case	case	NOUN
dpc-4512	4	52	report	report	NOUN
dpc-4512	4	53	.	.	PUNCT
dpc-4512	5	1	dermatol	dermatol	NOUN
dpc-4512	5	2	pract	pract	PROPN
dpc-4512	5	3	concept	concept	NOUN
dpc-4512	5	4	.	.	PUNCT
dpc-4512	6	1	2024;14(4):e2024252	2024;14(4):e2024252	NUM
dpc-4512	6	2	.	.	PUNCT
dpc-4512	6	3	doi	doi	PROPN
dpc-4512	6	4	:	:	PUNCT
dpc-4512	6	5	https://doi.org/10.5826/dpc.1404a252	https://doi.org/10.5826/dpc.1404a252	PROPN
dpc-4512	6	6	accepted	accept	VERB
dpc-4512	6	7	:	:	PUNCT
dpc-4512	6	8	may	may	AUX
dpc-4512	6	9	15	15	NUM
dpc-4512	6	10	,	,	PUNCT
dpc-4512	6	11	2024	2024	NUM
dpc-4512	6	12	;	;	PUNCT
dpc-4512	6	13	published	publish	VERB
dpc-4512	6	14	:	:	PUNCT
dpc-4512	7	1	october	october	PROPN
dpc-4512	7	2	2024	2024	NUM
dpc-4512	7	3	copyright	copyright	NOUN
dpc-4512	7	4	:	:	PUNCT
dpc-4512	7	5	©	©	PROPN
dpc-4512	7	6	2024	2024	NUM
dpc-4512	7	7	edek	edek	NOUN
dpc-4512	7	8	et	et	PROPN
dpc-4512	7	9	al	al	PROPN
dpc-4512	7	10	.	.	PUNCT
dpc-4512	8	1	this	this	PRON
dpc-4512	8	2	is	be	AUX
dpc-4512	8	3	an	an	DET
dpc-4512	8	4	open	open	ADJ
dpc-4512	8	5	-	-	PUNCT
dpc-4512	8	6	access	access	NOUN
dpc-4512	8	7	article	article	NOUN
dpc-4512	8	8	distributed	distribute	VERB
dpc-4512	8	9	under	under	ADP
dpc-4512	8	10	the	the	DET
dpc-4512	8	11	terms	term	NOUN
dpc-4512	8	12	of	of	ADP
dpc-4512	8	13	the	the	DET
dpc-4512	8	14	creative	creative	ADJ
dpc-4512	8	15	commons	common	NOUN
dpc-4512	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4512	8	17	license	license	NOUN
dpc-4512	8	18	(	(	PUNCT
dpc-4512	8	19	by	by	ADP
dpc-4512	8	20	-	-	PUNCT
dpc-4512	8	21	nc-4.0	nc-4.0	NOUN
dpc-4512	8	22	)	)	PUNCT
dpc-4512	8	23	,	,	PUNCT
dpc-4512	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4512	8	25	,	,	PUNCT
dpc-4512	8	26	which	which	PRON
dpc-4512	8	27	permits	permit	VERB
dpc-4512	8	28	unrestricted	unrestricted	ADJ
dpc-4512	8	29	noncommercial	noncommercial	ADJ
dpc-4512	8	30	use	use	NOUN
dpc-4512	8	31	,	,	PUNCT
dpc-4512	8	32	distribution	distribution	NOUN
dpc-4512	8	33	,	,	PUNCT
dpc-4512	8	34	and	and	CCONJ
dpc-4512	8	35	reproduction	reproduction	NOUN
dpc-4512	8	36	in	in	ADP
dpc-4512	8	37	any	any	DET
dpc-4512	8	38	medium	medium	NOUN
dpc-4512	8	39	,	,	PUNCT
dpc-4512	8	40	provided	provide	VERB
dpc-4512	8	41	the	the	DET
dpc-4512	8	42	original	original	ADJ
dpc-4512	8	43	authors	author	NOUN
dpc-4512	8	44	and	and	CCONJ
dpc-4512	8	45	source	source	NOUN
dpc-4512	8	46	are	be	AUX
dpc-4512	8	47	credited	credit	VERB
dpc-4512	8	48	.	.	PUNCT
dpc-4512	9	1	funding	funding	NOUN
dpc-4512	9	2	:	:	PUNCT
dpc-4512	9	3	none	none	NOUN
dpc-4512	9	4	.	.	PUNCT
dpc-4512	10	1	competing	compete	VERB
dpc-4512	10	2	interests	interest	NOUN
dpc-4512	10	3	:	:	PUNCT
dpc-4512	10	4	none	none	NOUN
dpc-4512	10	5	.	.	PUNCT
dpc-4512	11	1	authorship	authorship	NOUN
dpc-4512	11	2	:	:	PUNCT
dpc-4512	11	3	all	all	DET
dpc-4512	11	4	authors	author	NOUN
dpc-4512	11	5	have	have	AUX
dpc-4512	11	6	contributed	contribute	VERB
dpc-4512	11	7	significantly	significantly	ADV
dpc-4512	11	8	to	to	ADP
dpc-4512	11	9	this	this	DET
dpc-4512	11	10	publication	publication	NOUN
dpc-4512	11	11	.	.	PUNCT
dpc-4512	12	1	corresponding	correspond	VERB
dpc-4512	12	2	author	author	NOUN
dpc-4512	12	3	:	:	PUNCT
dpc-4512	12	4	yusuf	yusuf	PROPN
dpc-4512	12	5	can	can	AUX
dpc-4512	12	6	edek	edek	NOUN
dpc-4512	12	7	,	,	PUNCT
dpc-4512	12	8	gazi	gazi	PROPN
dpc-4512	12	9	universitesi	universitesi	PROPN
dpc-4512	12	10	tip	tip	PROPN
dpc-4512	12	11	fakultesi	fakultesi	PROPN
dpc-4512	12	12	hastanesi	hastanesi	NOUN
dpc-4512	12	13	,	,	PUNCT
dpc-4512	12	14	emniyet	emniyet	NOUN
dpc-4512	12	15	mahallesi	mahallesi	NOUN
dpc-4512	12	16	,	,	PUNCT
dpc-4512	12	17	mevlana	mevlana	NOUN
dpc-4512	12	18	bulvari	bulvari	NOUN
dpc-4512	12	19	,	,	PUNCT
dpc-4512	12	20	no:29	no:29	PROPN
dpc-4512	12	21	,	,	PUNCT
dpc-4512	12	22	06560	06560	NUM
dpc-4512	12	23	ankara	ankara	PROPN
dpc-4512	12	24	,	,	PUNCT
dpc-4512	12	25	turkey	turkey	PROPN
dpc-4512	12	26	.	.	PUNCT
dpc-4512	13	1	phone	phone	NOUN
dpc-4512	13	2	:	:	PUNCT
dpc-4512	14	1	+903122026129/+905062818274	+903122026129/+905062818274	X
dpc-4512	14	2	.	.	PUNCT
dpc-4512	15	1	e	e	NOUN
dpc-4512	15	2	-	-	NOUN
dpc-4512	15	3	mail	mail	NOUN
dpc-4512	15	4	:	:	PUNCT
dpc-4512	15	5	yusuf-can-35@hotmail.com	yusuf-can-35@hotmail.com	X
dpc-4512	15	6	introduction	introduction	NOUN
dpc-4512	15	7	urticarial	urticarial	PROPN
dpc-4512	15	8	vasculitis	vasculitis	PROPN
dpc-4512	15	9	is	be	AUX
dpc-4512	15	10	a	a	DET
dpc-4512	15	11	small	small	ADJ
dpc-4512	15	12	-	-	PUNCT
dpc-4512	15	13	vessel	vessel	NOUN
dpc-4512	15	14	vasculitis	vasculitis	ADJ
dpc-4512	15	15	type	type	NOUN
dpc-4512	15	16	that	that	PRON
dpc-4512	15	17	can	can	AUX
dpc-4512	15	18	be	be	AUX
dpc-4512	15	19	difficult	difficult	ADJ
dpc-4512	15	20	to	to	PART
dpc-4512	15	21	distinguish	distinguish	VERB
dpc-4512	15	22	from	from	ADP
dpc-4512	15	23	chronic	chronic	ADJ
dpc-4512	15	24	idiopathic	idiopathic	ADJ
dpc-4512	15	25	urticaria	urticaria	NOUN
dpc-4512	15	26	.	.	PUNCT
dpc-4512	16	1	lesions	lesion	NOUN
dpc-4512	16	2	that	that	PRON
dpc-4512	16	3	persist	persist	VERB
dpc-4512	16	4	longer	long	ADV
dpc-4512	16	5	than	than	ADP
dpc-4512	16	6	24	24	NUM
dpc-4512	16	7	hours	hour	NOUN
dpc-4512	16	8	,	,	PUNCT
dpc-4512	16	9	along	along	ADP
dpc-4512	16	10	with	with	ADP
dpc-4512	16	11	the	the	DET
dpc-4512	16	12	associated	associated	ADJ
dpc-4512	16	13	burning	burning	NOUN
dpc-4512	16	14	sensation	sensation	NOUN
dpc-4512	16	15	and	and	CCONJ
dpc-4512	16	16	hyperpigmentation	hyperpigmentation	NOUN
dpc-4512	16	17	,	,	PUNCT
dpc-4512	16	18	can	can	AUX
dpc-4512	16	19	aid	aid	VERB
dpc-4512	16	20	  	  	SPACE
dpc-4512	16	21	in	in	ADP
dpc-4512	16	22	identifying	identify	VERB
dpc-4512	16	23	urticarial	urticarial	ADJ
dpc-4512	16	24	vasculitis	vasculitis	NOUN
dpc-4512	16	25	.	.	PUNCT
dpc-4512	17	1	while	while	SCONJ
dpc-4512	17	2	elevated	elevated	ADJ
dpc-4512	17	3	sedimentation	sedimentation	NOUN
dpc-4512	17	4	rate	rate	NOUN
dpc-4512	17	5	and	and	CCONJ
dpc-4512	17	6	hypocomplementemia	hypocomplementemia	NOUN
dpc-4512	17	7	are	be	AUX
dpc-4512	17	8	common	common	ADJ
dpc-4512	17	9	laboratory	laboratory	NOUN
dpc-4512	17	10	abnormalities	abnormality	NOUN
dpc-4512	17	11	in	in	ADP
dpc-4512	17	12	urticarial	urticarial	ADJ
dpc-4512	17	13	vasculitis	vasculitis	PROPN
dpc-4512	17	14	,	,	PUNCT
dpc-4512	17	15	histopathological	histopathological	ADJ
dpc-4512	17	16	analysis	analysis	NOUN
dpc-4512	17	17	may	may	AUX
dpc-4512	17	18	show	show	VERB
dpc-4512	17	19	features	feature	NOUN
dpc-4512	17	20	of	of	ADP
dpc-4512	17	21	leukocytoclastic	leukocytoclastic	ADJ
dpc-4512	17	22	vasculitis	vasculitis	PROPN
dpc-4512	17	23	.	.	PUNCT
dpc-4512	18	1	treatment	treatment	NOUN
dpc-4512	18	2	options	option	NOUN
dpc-4512	18	3	for	for	ADP
dpc-4512	18	4	urticarial	urticarial	ADJ
dpc-4512	18	5	vasculitis	vasculiti	NOUN
dpc-4512	18	6	include	include	VERB
dpc-4512	18	7	antihistamines	antihistamine	NOUN
dpc-4512	18	8	,	,	PUNCT
dpc-4512	18	9	systemic	systemic	ADJ
dpc-4512	18	10	steroids	steroid	NOUN
dpc-4512	18	11	,	,	PUNCT
dpc-4512	18	12	colchicine	colchicine	PROPN
dpc-4512	18	13	,	,	PUNCT
dpc-4512	18	14	cyclosporine	cyclosporine	NOUN
dpc-4512	18	15	,	,	PUNCT
dpc-4512	18	16	methotrexate	methotrexate	NOUN
dpc-4512	18	17	,	,	PUNCT
dpc-4512	18	18	and	and	CCONJ
dpc-4512	18	19	omalizumab	omalizumab	NOUN
dpc-4512	19	1	[	[	X
dpc-4512	19	2	1,2	1,2	NUM
dpc-4512	19	3	]	]	PUNCT
dpc-4512	19	4	.	.	PUNCT
dpc-4512	20	1	herein	herein	NOUN
dpc-4512	20	2	,	,	PUNCT
dpc-4512	20	3	we	we	PRON
dpc-4512	20	4	present	present	VERB
dpc-4512	20	5	a	a	DET
dpc-4512	20	6	pediatric	pediatric	ADJ
dpc-4512	20	7	urticarial	urticarial	ADJ
dpc-4512	20	8	vasculitis	vasculitis	NOUN
dpc-4512	20	9	case	case	NOUN
dpc-4512	20	10	secondary	secondary	ADJ
dpc-4512	20	11	to	to	ADP
dpc-4512	20	12	sars	sar	NOUN
dpc-4512	20	13	-	-	PUNCT
dpc-4512	20	14	cov-2	cov-2	PART
dpc-4512	20	15	infection	infection	NOUN
dpc-4512	20	16	,	,	PUNCT
dpc-4512	20	17	treated	treat	VERB
dpc-4512	20	18	with	with	ADP
dpc-4512	20	19	omalizumab	omalizumab	NOUN
dpc-4512	20	20	.	.	PUNCT
dpc-4512	21	1	case	case	NOUN
dpc-4512	21	2	presentation	presentation	NOUN
dpc-4512	21	3	a	a	DET
dpc-4512	21	4	6	6	NUM
dpc-4512	21	5	-	-	PUNCT
dpc-4512	21	6	year	year	NOUN
dpc-4512	21	7	-	-	PUNCT
dpc-4512	21	8	old	old	ADJ
dpc-4512	21	9	healthy	healthy	ADJ
dpc-4512	21	10	boy	boy	NOUN
dpc-4512	21	11	presented	present	VERB
dpc-4512	21	12	to	to	ADP
dpc-4512	21	13	our	our	PRON
dpc-4512	21	14	clinic	clinic	NOUN
dpc-4512	21	15	due	due	ADP
dpc-4512	21	16	to	to	ADP
dpc-4512	21	17	itchy	itchy	ADJ
dpc-4512	21	18	rashes	rash	NOUN
dpc-4512	21	19	.	.	PUNCT
dpc-4512	22	1	his	his	PRON
dpc-4512	22	2	parents	parent	NOUN
dpc-4512	22	3	described	describe	VERB
dpc-4512	22	4	that	that	SCONJ
dpc-4512	22	5	the	the	DET
dpc-4512	22	6	lesions	lesion	NOUN
dpc-4512	22	7	began	begin	VERB
dpc-4512	22	8	on	on	ADP
dpc-4512	22	9	the	the	DET
dpc-4512	22	10	leg	leg	NOUN
dpc-4512	22	11	10	10	NUM
dpc-4512	22	12	days	day	NOUN
dpc-4512	22	13	after	after	ADP
dpc-4512	22	14	the	the	DET
dpc-4512	22	15	sars	sar	NOUN
dpc-4512	22	16	-	-	PUNCT
dpc-4512	22	17	cov-2	cov-2	PART
dpc-4512	22	18	infection	infection	NOUN
dpc-4512	22	19	diagnosis	diagnosis	NOUN
dpc-4512	22	20	six	six	NUM
dpc-4512	22	21	months	month	NOUN
dpc-4512	22	22	earlier	early	ADV
dpc-4512	22	23	and	and	CCONJ
dpc-4512	22	24	that	that	SCONJ
dpc-4512	22	25	the	the	DET
dpc-4512	22	26	lesions	lesion	NOUN
dpc-4512	22	27	had	have	AUX
dpc-4512	22	28	spread	spread	VERB
dpc-4512	22	29	over	over	ADP
dpc-4512	22	30	time	time	NOUN
dpc-4512	22	31	.	.	PUNCT
dpc-4512	23	1	dermatological	dermatological	ADJ
dpc-4512	23	2	examination	examination	NOUN
dpc-4512	23	3	showed	show	VERB
dpc-4512	23	4	annular	annular	ADJ
dpc-4512	23	5	urticarial	urticarial	ADJ
dpc-4512	23	6	plaques	plaque	NOUN
dpc-4512	23	7	,	,	PUNCT
dpc-4512	23	8	purpuras	purpura	NOUN
dpc-4512	23	9	,	,	PUNCT
dpc-4512	23	10	and	and	CCONJ
dpc-4512	23	11	hyperpigmented	hyperpigmente	VERB
dpc-4512	23	12	patches	patch	NOUN
dpc-4512	23	13	on	on	ADP
dpc-4512	23	14	the	the	DET
dpc-4512	23	15	trunk	trunk	NOUN
dpc-4512	23	16	,	,	PUNCT
dpc-4512	23	17	extremities	extremity	NOUN
dpc-4512	23	18	,	,	PUNCT
dpc-4512	23	19	and	and	CCONJ
dpc-4512	23	20	face	face	NOUN
dpc-4512	23	21	(	(	PUNCT
dpc-4512	23	22	figure	figure	NOUN
dpc-4512	23	23	1	1	NUM
dpc-4512	23	24	)	)	PUNCT
dpc-4512	23	25	.	.	PUNCT
dpc-4512	24	1	histopathological	histopathological	ADJ
dpc-4512	24	2	analysis	analysis	NOUN
dpc-4512	24	3	of	of	ADP
dpc-4512	24	4	the	the	DET
dpc-4512	24	5	punch	punch	NOUN
dpc-4512	24	6	biopsy	biopsy	NOUN
dpc-4512	24	7	of	of	ADP
dpc-4512	24	8	the	the	DET
dpc-4512	24	9	urticarial	urticarial	ADJ
dpc-4512	24	10	plaque	plaque	NOUN
dpc-4512	24	11	on	on	ADP
dpc-4512	24	12	the	the	DET
dpc-4512	24	13	trunk	trunk	NOUN
dpc-4512	24	14	showed	show	VERB
dpc-4512	24	15	perivascular	perivascular	ADJ
dpc-4512	24	16	dermal	dermal	NOUN
dpc-4512	24	17	infiltration	infiltration	NOUN
dpc-4512	24	18	,	,	PUNCT
dpc-4512	24	19	endothelial	endothelial	ADJ
dpc-4512	24	20	swelling	swelling	NOUN
dpc-4512	24	21	,	,	PUNCT
dpc-4512	24	22	and	and	CCONJ
dpc-4512	24	23	leukocytoclasia	leukocytoclasia	NOUN
dpc-4512	24	24	.	.	PUNCT
dpc-4512	25	1	while	while	SCONJ
dpc-4512	25	2	laboratory	laboratory	NOUN
dpc-4512	25	3	evaluation	evaluation	NOUN
dpc-4512	25	4	revealed	reveal	VERB
dpc-4512	25	5	a	a	DET
dpc-4512	25	6	high	high	ADJ
dpc-4512	25	7	immunoglobulin	immunoglobulin	NOUN
dpc-4512	25	8	level	level	NOUN
dpc-4512	25	9	(	(	PUNCT
dpc-4512	25	10	1030	1030	NUM
dpc-4512	25	11	ku	ku	PROPN
dpc-4512	25	12	/	/	SYM
dpc-4512	25	13	l	l	PROPN
dpc-4512	25	14	)	)	PUNCT
dpc-4512	25	15	,	,	PUNCT
dpc-4512	25	16	the	the	DET
dpc-4512	25	17	complement	complement	NOUN
dpc-4512	25	18	levels	level	NOUN
dpc-4512	25	19	were	be	AUX
dpc-4512	25	20	evaluated	evaluate	VERB
dpc-4512	25	21	as	as	ADP
dpc-4512	25	22	normal	normal	ADJ
dpc-4512	25	23	.	.	PUNCT
dpc-4512	26	1	the	the	DET
dpc-4512	26	2	patient	patient	NOUN
dpc-4512	26	3	was	be	AUX
dpc-4512	26	4	diagnosed	diagnose	VERB
dpc-4512	26	5	with	with	ADP
dpc-4512	26	6	normocomplementemic	normocomplementemic	ADJ
dpc-4512	26	7	urticarial	urticarial	PROPN
dpc-4512	26	8	vasculitis	vasculitis	PROPN
dpc-4512	26	9	based	base	VERB
dpc-4512	26	10	on	on	ADP
dpc-4512	26	11	clinical	clinical	ADJ
dpc-4512	26	12	examination	examination	NOUN
dpc-4512	26	13	and	and	CCONJ
dpc-4512	26	14	histopathological	histopathological	ADJ
dpc-4512	26	15	findings	finding	NOUN
dpc-4512	26	16	.	.	PUNCT
dpc-4512	27	1	considering	consider	VERB
dpc-4512	27	2	the	the	DET
dpc-4512	27	3	time	time	NOUN
dpc-4512	27	4	of	of	ADP
dpc-4512	27	5	development	development	NOUN
dpc-4512	27	6	of	of	ADP
dpc-4512	27	7	the	the	DET
dpc-4512	27	8	complaints	complaint	NOUN
dpc-4512	27	9	and	and	CCONJ
dpc-4512	27	10	the	the	DET
dpc-4512	27	11	absence	absence	NOUN
dpc-4512	27	12	of	of	ADP
dpc-4512	27	13	any	any	DET
dpc-4512	27	14	other	other	ADJ
dpc-4512	27	15	triggering	trigger	VERB
dpc-4512	27	16	factors	factor	NOUN
dpc-4512	27	17	,	,	PUNCT
dpc-4512	27	18	it	it	PRON
dpc-4512	27	19	was	be	AUX
dpc-4512	27	20	concluded	conclude	VERB
dpc-4512	27	21	that	that	SCONJ
dpc-4512	27	22	the	the	DET
dpc-4512	27	23	urticarial	urticarial	NOUN
dpc-4512	27	24	vasculitis	vasculitis	PROPN
dpc-4512	27	25	developed	develop	VERB
dpc-4512	27	26	secondary	secondary	ADJ
dpc-4512	27	27	to	to	ADP
dpc-4512	27	28	the	the	DET
dpc-4512	27	29	sars	sar	NOUN
dpc-4512	27	30	-	-	PUNCT
dpc-4512	27	31	cov-2	cov-2	NOUN
dpc-4512	27	32	infection	infection	NOUN
dpc-4512	27	33	.	.	PUNCT
dpc-4512	28	1	following	follow	VERB
dpc-4512	28	2	oral	oral	ADJ
dpc-4512	28	3	prednisolone	prednisolone	PROPN
dpc-4512	28	4	(	(	PUNCT
dpc-4512	28	5	1	1	NUM
dpc-4512	28	6	mg	mg	PROPN
dpc-4512	28	7	/	/	SYM
dpc-4512	28	8	kg	kg	NOUN
dpc-4512	28	9	)	)	PUNCT
dpc-4512	28	10	and	and	CCONJ
dpc-4512	28	11	desloratadine	desloratadine	NOUN
dpc-4512	28	12	treatment	treatment	NOUN
dpc-4512	28	13	,	,	PUNCT
dpc-4512	28	14	complete	complete	ADJ
dpc-4512	28	15	treatment	treatment	NOUN
dpc-4512	28	16	response	response	NOUN
dpc-4512	28	17	was	be	AUX
dpc-4512	28	18	detected	detect	VERB
dpc-4512	28	19	,	,	PUNCT
dpc-4512	28	20	and	and	CCONJ
dpc-4512	28	21	steroid	steroid	NOUN
dpc-4512	28	22	treatment	treatment	NOUN
dpc-4512	28	23	was	be	AUX
dpc-4512	28	24	tapered	taper	VERB
dpc-4512	28	25	.	.	PUNCT
dpc-4512	29	1	when	when	SCONJ
dpc-4512	29	2	the	the	DET
dpc-4512	29	3	patient	patient	NOUN
dpc-4512	29	4	’s	’s	PART
dpc-4512	29	5	complaints	complaint	NOUN
dpc-4512	29	6	recurred	recur	VERB
dpc-4512	29	7	while	while	SCONJ
dpc-4512	29	8	the	the	DET
dpc-4512	29	9	steroid	steroid	NOUN
dpc-4512	29	10	dose	dose	NOUN
dpc-4512	29	11	was	be	AUX
dpc-4512	29	12	reduced	reduce	VERB
dpc-4512	29	13	,	,	PUNCT
dpc-4512	29	14	omalizumab	omalizumab	NOUN
dpc-4512	29	15	treatment	treatment	NOUN
dpc-4512	29	16	was	be	AUX
dpc-4512	29	17	chosen	choose	VERB
dpc-4512	29	18	since	since	SCONJ
dpc-4512	29	19	2	2	NUM
dpc-4512	29	20	research	research	NOUN
dpc-4512	29	21	letter	letter	NOUN
dpc-4512	29	22	|	|	ADV
dpc-4512	29	23	dermatol	dermatol	ADJ
dpc-4512	29	24	pract	pract	NOUN
dpc-4512	29	25	concept	concept	NOUN
dpc-4512	29	26	.	.	PUNCT
dpc-4512	30	1	2024;14(4):e2024252	2024;14(4):e2024252	NUM
dpc-4512	30	2	literature	literature	NOUN
dpc-4512	30	3	data	datum	NOUN
dpc-4512	30	4	indicates	indicate	VERB
dpc-4512	30	5	that	that	SCONJ
dpc-4512	30	6	it	it	PRON
dpc-4512	30	7	is	be	AUX
dpc-4512	30	8	beneficial	beneficial	ADJ
dpc-4512	30	9	for	for	ADP
dpc-4512	30	10	treating	treat	VERB
dpc-4512	30	11	urticarial	urticarial	ADJ
dpc-4512	30	12	vasculitis	vasculitis	NOUN
dpc-4512	30	13	and	and	CCONJ
dpc-4512	30	14	is	be	AUX
dpc-4512	30	15	a	a	DET
dpc-4512	30	16	safe	safe	ADJ
dpc-4512	30	17	medication	medication	NOUN
dpc-4512	30	18	in	in	ADP
dpc-4512	30	19	terms	term	NOUN
dpc-4512	30	20	of	of	ADP
dpc-4512	30	21	side	side	NOUN
dpc-4512	30	22	effects	effect	NOUN
dpc-4512	30	23	.	.	PUNCT
dpc-4512	31	1	omalizumab	omalizumab	NOUN
dpc-4512	31	2	treatment	treatment	NOUN
dpc-4512	31	3	was	be	AUX
dpc-4512	31	4	administered	administer	VERB
dpc-4512	31	5	subcutaneously	subcutaneously	ADV
dpc-4512	31	6	for	for	ADP
dpc-4512	31	7	150	150	NUM
dpc-4512	31	8	mg/4	mg/4	NOUN
dpc-4512	31	9	weeks	week	NOUN
dpc-4512	31	10	,	,	PUNCT
dpc-4512	31	11	and	and	CCONJ
dpc-4512	31	12	at	at	ADP
dpc-4512	31	13	the	the	DET
dpc-4512	31	14	1	1	NUM
dpc-4512	31	15	-	-	PUNCT
dpc-4512	31	16	year	year	NOUN
dpc-4512	31	17	follow	follow	NOUN
dpc-4512	31	18	-	-	PUNCT
dpc-4512	31	19	up	up	NOUN
dpc-4512	31	20	,	,	PUNCT
dpc-4512	31	21	the	the	DET
dpc-4512	31	22	patient	patient	NOUN
dpc-4512	31	23	’s	’s	PART
dpc-4512	31	24	symptoms	symptom	NOUN
dpc-4512	31	25	had	have	AUX
dpc-4512	31	26	regressed	regress	VERB
dpc-4512	31	27	without	without	ADP
dpc-4512	31	28	any	any	DET
dpc-4512	31	29	recurrence	recurrence	NOUN
dpc-4512	31	30	or	or	CCONJ
dpc-4512	31	31	side	side	NOUN
dpc-4512	31	32	effects	effect	NOUN
dpc-4512	31	33	.	.	PUNCT
dpc-4512	32	1	discussion	discussion	NOUN
dpc-4512	32	2	while	while	SCONJ
dpc-4512	32	3	the	the	DET
dpc-4512	32	4	etiology	etiology	NOUN
dpc-4512	32	5	of	of	ADP
dpc-4512	32	6	urticarial	urticarial	ADJ
dpc-4512	32	7	vasculitis	vasculitis	PROPN
dpc-4512	32	8	may	may	AUX
dpc-4512	32	9	be	be	AUX
dpc-4512	32	10	idiopathic	idiopathic	ADJ
dpc-4512	32	11	,	,	PUNCT
dpc-4512	32	12	malignancies	malignancy	NOUN
dpc-4512	32	13	,	,	PUNCT
dpc-4512	32	14	connective	connective	ADJ
dpc-4512	32	15	tissue	tissue	NOUN
dpc-4512	32	16	diseases	disease	NOUN
dpc-4512	32	17	,	,	PUNCT
dpc-4512	32	18	and	and	CCONJ
dpc-4512	32	19	infections	infection	NOUN
dpc-4512	32	20	also	also	ADV
dpc-4512	32	21	can	can	AUX
dpc-4512	32	22	be	be	AUX
dpc-4512	32	23	a	a	DET
dpc-4512	32	24	triggering	trigger	VERB
dpc-4512	32	25	factor	factor	NOUN
dpc-4512	32	26	.	.	PUNCT
dpc-4512	33	1	in	in	ADP
dpc-4512	33	2	the	the	DET
dpc-4512	33	3	literature	literature	NOUN
dpc-4512	33	4	,	,	PUNCT
dpc-4512	33	5	several	several	ADJ
dpc-4512	33	6	skin	skin	NOUN
dpc-4512	33	7	conditions	condition	NOUN
dpc-4512	33	8	linked	link	VERB
dpc-4512	33	9	to	to	ADP
dpc-4512	33	10	sars	sar	NOUN
dpc-4512	33	11	-	-	PUNCT
dpc-4512	33	12	cov-2	cov-2	PART
dpc-4512	33	13	have	have	AUX
dpc-4512	33	14	been	be	AUX
dpc-4512	33	15	described	describe	VERB
dpc-4512	33	16	,	,	PUNCT
dpc-4512	33	17	with	with	ADP
dpc-4512	33	18	urticarial	urticarial	ADJ
dpc-4512	33	19	vasculitis	vasculiti	NOUN
dpc-4512	33	20	being	be	AUX
dpc-4512	33	21	one	one	NUM
dpc-4512	33	22	of	of	ADP
dpc-4512	33	23	them	they	PRON
dpc-4512	33	24	.	.	PUNCT
dpc-4512	34	1	the	the	DET
dpc-4512	34	2	exact	exact	ADJ
dpc-4512	34	3	pathogenesis	pathogenesis	NOUN
dpc-4512	34	4	of	of	ADP
dpc-4512	34	5	sars	sar	NOUN
dpc-4512	34	6	-	-	PUNCT
dpc-4512	34	7	cov-2	cov-2	ADV
dpc-4512	34	8	-	-	PUNCT
dpc-4512	34	9	induced	induce	VERB
dpc-4512	34	10	urticarial	urticarial	NOUN
dpc-4512	34	11	vasculitis	vasculitis	PROPN
dpc-4512	34	12	remains	remain	VERB
dpc-4512	34	13	unknown	unknown	ADJ
dpc-4512	34	14	;	;	PUNCT
dpc-4512	34	15	however	however	ADV
dpc-4512	34	16	,	,	PUNCT
dpc-4512	34	17	virus	virus	NOUN
dpc-4512	34	18	-	-	PUNCT
dpc-4512	34	19	mediated	mediate	VERB
dpc-4512	34	20	endothelial	endothelial	ADJ
dpc-4512	34	21	cell	cell	NOUN
dpc-4512	34	22	damage	damage	NOUN
dpc-4512	34	23	and	and	CCONJ
dpc-4512	34	24	immune	immune	ADJ
dpc-4512	34	25	system	system	NOUN
dpc-4512	34	26	dysregulation	dysregulation	NOUN
dpc-4512	34	27	,	,	PUNCT
dpc-4512	34	28	as	as	SCONJ
dpc-4512	34	29	immune	immune	ADJ
dpc-4512	34	30	complex	complex	ADJ
dpc-4512	34	31	deposition	deposition	NOUN
dpc-4512	34	32	and	and	CCONJ
dpc-4512	34	33	complement	complement	NOUN
dpc-4512	34	34	-	-	PUNCT
dpc-4512	34	35	induced	induce	VERB
dpc-4512	34	36	cytotoxicity	cytotoxicity	NOUN
dpc-4512	34	37	play	play	VERB
dpc-4512	34	38	a	a	DET
dpc-4512	34	39	role	role	NOUN
dpc-4512	34	40	in	in	ADP
dpc-4512	34	41	the	the	DET
dpc-4512	34	42	pathogenesis	pathogenesis	NOUN
dpc-4512	34	43	[	[	X
dpc-4512	34	44	1,3	1,3	NUM
dpc-4512	34	45	]	]	PUNCT
dpc-4512	34	46	.	.	PUNCT
dpc-4512	35	1	treatment	treatment	NOUN
dpc-4512	35	2	of	of	ADP
dpc-4512	35	3	urticarial	urticarial	ADJ
dpc-4512	35	4	vasculitis	vasculitis	PROPN
dpc-4512	35	5	in	in	ADP
dpc-4512	35	6	pediatric	pediatric	ADJ
dpc-4512	35	7	cases	case	NOUN
dpc-4512	35	8	is	be	AUX
dpc-4512	35	9	challenging	challenge	VERB
dpc-4512	35	10	due	due	ADJ
dpc-4512	35	11	to	to	ADP
dpc-4512	35	12	the	the	DET
dpc-4512	35	13	unsatisfactory	unsatisfactory	ADJ
dpc-4512	35	14	effectiveness	effectiveness	NOUN
dpc-4512	35	15	of	of	ADP
dpc-4512	35	16	antihistamines	antihistamine	NOUN
dpc-4512	35	17	and	and	CCONJ
dpc-4512	35	18	the	the	DET
dpc-4512	35	19	restrictive	restrictive	ADJ
dpc-4512	35	20	use	use	NOUN
dpc-4512	35	21	of	of	ADP
dpc-4512	35	22	long	long	ADJ
dpc-4512	35	23	-	-	PUNCT
dpc-4512	35	24	term	term	NOUN
dpc-4512	35	25	systemic	systemic	ADJ
dpc-4512	35	26	steroids	steroid	NOUN
dpc-4512	35	27	or	or	CCONJ
dpc-4512	35	28	immunosuppressive	immunosuppressive	ADJ
dpc-4512	35	29	agents	agent	NOUN
dpc-4512	35	30	due	due	ADP
dpc-4512	35	31	to	to	ADP
dpc-4512	35	32	side	side	ADJ
dpc-4512	35	33	effects	effect	NOUN
dpc-4512	35	34	[	[	X
dpc-4512	35	35	4	4	NUM
dpc-4512	35	36	]	]	PUNCT
dpc-4512	35	37	.	.	PUNCT
dpc-4512	36	1	omalizumab	omalizumab	NOUN
dpc-4512	36	2	is	be	AUX
dpc-4512	36	3	a	a	DET
dpc-4512	36	4	humanized	humanize	VERB
dpc-4512	36	5	monoclonal	monoclonal	NOUN
dpc-4512	36	6	antibody	antibody	NOUN
dpc-4512	36	7	targeting	target	VERB
dpc-4512	36	8	ige	ige	PROPN
dpc-4512	36	9	used	use	VERB
dpc-4512	36	10	in	in	ADP
dpc-4512	36	11	chronic	chronic	ADJ
dpc-4512	36	12	spontaneous	spontaneous	ADJ
dpc-4512	36	13	urticaria	urticaria	NOUN
dpc-4512	36	14	treatment	treatment	NOUN
dpc-4512	36	15	.	.	PUNCT
dpc-4512	37	1	recent	recent	ADJ
dpc-4512	37	2	studies	study	NOUN
dpc-4512	37	3	have	have	AUX
dpc-4512	37	4	shown	show	VERB
dpc-4512	37	5	that	that	SCONJ
dpc-4512	37	6	omalizumab	omalizumab	NOUN
dpc-4512	37	7	is	be	AUX
dpc-4512	37	8	effective	effective	ADJ
dpc-4512	37	9	in	in	ADP
dpc-4512	37	10	treating	treat	VERB
dpc-4512	37	11	urticarial	urticarial	ADJ
dpc-4512	37	12	vasculitis	vasculitis	PROPN
dpc-4512	38	1	[	[	X
dpc-4512	38	2	5	5	NUM
dpc-4512	38	3	]	]	PUNCT
dpc-4512	38	4	.	.	PUNCT
dpc-4512	39	1	wang	wang	PROPN
dpc-4512	39	2	et	et	PROPN
dpc-4512	39	3	al	al	PROPN
dpc-4512	39	4	.	.	PROPN
dpc-4512	39	5	reported	report	VERB
dpc-4512	39	6	that	that	SCONJ
dpc-4512	39	7	four	four	NUM
dpc-4512	39	8	pediatric	pediatric	ADJ
dpc-4512	39	9	urticarial	urticarial	ADJ
dpc-4512	39	10	vasculitis	vasculitis	ADJ
dpc-4512	39	11	patients	patient	NOUN
dpc-4512	39	12	unresponsive	unresponsive	ADJ
dpc-4512	39	13	to	to	ADP
dpc-4512	39	14	systemic	systemic	ADJ
dpc-4512	39	15	steroid	steroid	NOUN
dpc-4512	39	16	treatment	treatment	NOUN
dpc-4512	39	17	were	be	AUX
dpc-4512	39	18	successfully	successfully	ADV
dpc-4512	39	19	treated	treat	VERB
dpc-4512	39	20	with	with	ADP
dpc-4512	39	21	omalizumab	omalizumab	NOUN
dpc-4512	39	22	without	without	ADP
dpc-4512	39	23	any	any	DET
dpc-4512	39	24	side	side	NOUN
dpc-4512	39	25	effects	effect	NOUN
dpc-4512	39	26	or	or	CCONJ
dpc-4512	39	27	recurrence	recurrence	NOUN
dpc-4512	39	28	[	[	X
dpc-4512	39	29	4	4	NUM
dpc-4512	39	30	]	]	PUNCT
dpc-4512	39	31	.	.	PUNCT
dpc-4512	40	1	conclusion	conclusion	NOUN
dpc-4512	40	2	we	we	PRON
dpc-4512	40	3	would	would	AUX
dpc-4512	40	4	like	like	VERB
dpc-4512	40	5	to	to	PART
dpc-4512	40	6	highlight	highlight	VERB
dpc-4512	40	7	with	with	ADP
dpc-4512	40	8	this	this	DET
dpc-4512	40	9	case	case	NOUN
dpc-4512	40	10	report	report	NOUN
dpc-4512	40	11	that	that	SCONJ
dpc-4512	40	12	urticarial	urticarial	ADJ
dpc-4512	40	13	vasculitis	vasculitis	PROPN
dpc-4512	40	14	may	may	AUX
dpc-4512	40	15	be	be	AUX
dpc-4512	40	16	one	one	NUM
dpc-4512	40	17	of	of	ADP
dpc-4512	40	18	the	the	DET
dpc-4512	40	19	skin	skin	NOUN
dpc-4512	40	20	conditions	condition	NOUN
dpc-4512	40	21	linked	link	VERB
dpc-4512	40	22	with	with	ADP
dpc-4512	40	23	sars	sar	NOUN
dpc-4512	40	24	-	-	PUNCT
dpc-4512	40	25	cov-2	cov-2	NOUN
dpc-4512	40	26	and	and	CCONJ
dpc-4512	40	27	that	that	DET
dpc-4512	40	28	omalizumab	omalizumab	NOUN
dpc-4512	40	29	may	may	AUX
dpc-4512	40	30	be	be	AUX
dpc-4512	40	31	a	a	DET
dpc-4512	40	32	safe	safe	ADJ
dpc-4512	40	33	treatment	treatment	NOUN
dpc-4512	40	34	agent	agent	NOUN
dpc-4512	40	35	in	in	ADP
dpc-4512	40	36	pediatric	pediatric	ADJ
dpc-4512	40	37	urticarial	urticarial	ADJ
dpc-4512	40	38	vasculitis	vasculitis	ADJ
dpc-4512	40	39	cases	case	NOUN
dpc-4512	40	40	.	.	PUNCT
dpc-4512	41	1	references	reference	NOUN
dpc-4512	41	2	1	1	NUM
dpc-4512	41	3	.	.	PUNCT
dpc-4512	42	1	marzano	marzano	PROPN
dpc-4512	42	2	av	av	PROPN
dpc-4512	42	3	,	,	PUNCT
dpc-4512	42	4	maronese	maronese	PROPN
dpc-4512	42	5	ca	can	AUX
dpc-4512	42	6	,	,	PUNCT
dpc-4512	42	7	genovese	genovese	NOUN
dpc-4512	42	8	g	g	NOUN
dpc-4512	42	9	,	,	PUNCT
dpc-4512	42	10	et	et	PROPN
dpc-4512	42	11	al	al	PROPN
dpc-4512	42	12	.	.	PROPN
dpc-4512	43	1	urticarial	urticarial	PROPN
dpc-4512	43	2	vasculitis	vasculitis	PROPN
dpc-4512	43	3	:	:	PUNCT
dpc-4512	43	4	clinical	clinical	ADJ
dpc-4512	43	5	and	and	CCONJ
dpc-4512	43	6	laboratory	laboratory	NOUN
dpc-4512	43	7	findings	finding	NOUN
dpc-4512	43	8	with	with	ADP
dpc-4512	43	9	a	a	DET
dpc-4512	43	10	particular	particular	ADJ
dpc-4512	43	11	emphasis	emphasis	NOUN
dpc-4512	43	12	on	on	ADP
dpc-4512	43	13	differential	differential	ADJ
dpc-4512	43	14	diagnosis	diagnosis	NOUN
dpc-4512	43	15	.	.	PUNCT
dpc-4512	43	16	 	 	SPACE
dpc-4512	44	1	j	j	PROPN
dpc-4512	44	2	allergy	allergy	PROPN
dpc-4512	44	3	clin	clin	PROPN
dpc-4512	44	4	immunol	immunol	PROPN
dpc-4512	44	5	.	.	PUNCT
dpc-4512	45	1	2022	2022	NUM
dpc-4512	45	2	;	;	PUNCT
dpc-4512	45	3	149(4):1137	149(4):1137	PROPN
dpc-4512	45	4	-	-	SYM
dpc-4512	45	5	1149	1149	NUM
dpc-4512	45	6	.	.	PUNCT
dpc-4512	46	1	doi:10.1016	doi:10.1016	PROPN
dpc-4512	46	2	/	/	SYM
dpc-4512	46	3	j.jaci.2022.02.007	j.jaci.2022.02.007	PROPN
dpc-4512	46	4	2	2	NUM
dpc-4512	46	5	.	.	PUNCT
dpc-4512	46	6	kolkhir	kolkhir	PROPN
dpc-4512	46	7	p	p	NOUN
dpc-4512	46	8	,	,	PUNCT
dpc-4512	46	9	grakhova	grakhova	NOUN
dpc-4512	46	10	m	m	PROPN
dpc-4512	46	11	,	,	PUNCT
dpc-4512	46	12	bonnekoh	bonnekoh	NOUN
dpc-4512	46	13	h	h	NOUN
dpc-4512	46	14	,	,	PUNCT
dpc-4512	46	15	krause	krause	PROPN
dpc-4512	46	16	k	k	PROPN
dpc-4512	46	17	,	,	PUNCT
dpc-4512	46	18	maurer	maurer	PROPN
dpc-4512	46	19	m.	m.	PROPN
dpc-4512	46	20	treatment	treatment	NOUN
dpc-4512	46	21	of	of	ADP
dpc-4512	46	22	urticarial	urticarial	ADJ
dpc-4512	46	23	vasculitis	vasculitis	PROPN
dpc-4512	46	24	:	:	PUNCT
dpc-4512	46	25	a	a	DET
dpc-4512	46	26	 	 	SPACE
dpc-4512	46	27	systematic	systematic	ADJ
dpc-4512	46	28	review	review	NOUN
dpc-4512	46	29	.	.	PUNCT
dpc-4512	46	30	 	 	SPACE
dpc-4512	47	1	j	j	PROPN
dpc-4512	47	2	allergy	allergy	PROPN
dpc-4512	47	3	clin	clin	PROPN
dpc-4512	47	4	immunol	immunol	NOUN
dpc-4512	47	5	.	.	PUNCT
dpc-4512	48	1	2019;143(2):458	2019;143(2):458	NUM
dpc-4512	48	2	-	-	SYM
dpc-4512	48	3	466	466	NUM
dpc-4512	48	4	.	.	PUNCT
dpc-4512	48	5	doi:10.1016	doi:10.1016	PROPN
dpc-4512	48	6	/	/	SYM
dpc-4512	48	7	j.jaci.2018	j.jaci.2018	PROPN
dpc-4512	48	8	.09.007	.09.007	PUNCT
dpc-4512	49	1	3	3	X
dpc-4512	49	2	.	.	X
dpc-4512	49	3	de	de	X
dpc-4512	49	4	perosanz	perosanz	NOUN
dpc-4512	49	5	-	-	PUNCT
dpc-4512	49	6	lobo	lobo	PROPN
dpc-4512	49	7	d	d	PROPN
dpc-4512	49	8	,	,	PUNCT
dpc-4512	49	9	fernandez	fernandez	PROPN
dpc-4512	49	10	-	-	PUNCT
dpc-4512	49	11	nieto	nieto	PROPN
dpc-4512	49	12	d	d	PROPN
dpc-4512	49	13	,	,	PUNCT
dpc-4512	49	14	burgos	burgos	PROPN
dpc-4512	49	15	-	-	PROPN
dpc-4512	49	16	blasco	blasco	PROPN
dpc-4512	49	17	p	p	PROPN
dpc-4512	49	18	,	,	PUNCT
dpc-4512	49	19	et	et	PROPN
dpc-4512	49	20	al	al	PROPN
dpc-4512	49	21	.	.	PROPN
dpc-4512	49	22	urticarial	urticarial	PROPN
dpc-4512	49	23	vasculitis	vasculitis	PROPN
dpc-4512	49	24	in	in	ADP
dpc-4512	49	25	covid-19	covid-19	PROPN
dpc-4512	49	26	infection	infection	NOUN
dpc-4512	49	27	:	:	PUNCT
dpc-4512	49	28	a	a	DET
dpc-4512	49	29	vasculopathy	vasculopathy	NOUN
dpc-4512	49	30	related	relate	VERB
dpc-4512	49	31	symptom	symptom	NOUN
dpc-4512	49	32	?	?	PUNCT
dpc-4512	50	1	j	j	PROPN
dpc-4512	50	2	eur	eur	PROPN
dpc-4512	50	3	acad	acad	PROPN
dpc-4512	50	4	dermatol	dermatol	NOUN
dpc-4512	50	5	venereol	venereol	NOUN
dpc-4512	50	6	.	.	PUNCT
dpc-4512	51	1	2020;34(10	2020;34(10	NUM
dpc-4512	51	2	):	):	PUNCT
dpc-4512	51	3	e566	e566	PROPN
dpc-4512	51	4	-	-	PUNCT
dpc-4512	51	5	e568	e568	PROPN
dpc-4512	51	6	.	.	PUNCT
dpc-4512	52	1	doi:10.1111	doi:10.1111	PROPN
dpc-4512	52	2	/	/	SYM
dpc-4512	52	3	jdv.16713	jdv.16713	ADP
dpc-4512	52	4	4	4	NUM
dpc-4512	52	5	.	.	PUNCT
dpc-4512	53	1	wang	wang	PROPN
dpc-4512	53	2	s	s	PROPN
dpc-4512	53	3	,	,	PUNCT
dpc-4512	53	4	fu	fu	PROPN
dpc-4512	53	5	l	l	PROPN
dpc-4512	53	6	,	,	PUNCT
dpc-4512	53	7	xiang	xiang	PROPN
dpc-4512	53	8	x	x	PROPN
dpc-4512	53	9	,	,	PUNCT
dpc-4512	53	10	zhang	zhang	PROPN
dpc-4512	53	11	b	b	PROPN
dpc-4512	53	12	,	,	PUNCT
dpc-4512	53	13	ma	ma	PROPN
dpc-4512	53	14	l	l	PROPN
dpc-4512	53	15	,	,	PUNCT
dpc-4512	53	16	xing	xing	PROPN
dpc-4512	53	17	h.	h.	PROPN
dpc-4512	54	1	successful	successful	ADJ
dpc-4512	54	2	treatment	treatment	NOUN
dpc-4512	54	3	of	of	ADP
dpc-4512	54	4	urticarial	urticarial	NOUN
dpc-4512	54	5	vasculitis	vasculitis	PROPN
dpc-4512	54	6	with	with	ADP
dpc-4512	54	7	omalizumab	omalizumab	NOUN
dpc-4512	54	8	in	in	ADP
dpc-4512	54	9	children	child	NOUN
dpc-4512	54	10	:	:	PUNCT
dpc-4512	54	11	a	a	DET
dpc-4512	54	12	case	case	NOUN
dpc-4512	54	13	series	series	NOUN
dpc-4512	54	14	.	.	PUNCT
dpc-4512	54	15	 	 	SPACE
dpc-4512	54	16	clin	clin	PROPN
dpc-4512	54	17	exp	exp	NOUN
dpc-4512	54	18	dermatol	dermatol	NOUN
dpc-4512	54	19	.	.	PUNCT
dpc-4512	55	1	2023;48(10):1145	2023;48(10):1145	NUM
dpc-4512	55	2	-	-	SYM
dpc-4512	55	3	1148	1148	NUM
dpc-4512	55	4	.	.	PUNCT
dpc-4512	56	1	doi:10.1093	doi:10.1093	NOUN
dpc-4512	56	2	/ced	/ced	PROPN
dpc-4512	56	3	/	/	SYM
dpc-4512	56	4	llad192	llad192	PROPN
dpc-4512	56	5	5	5	NUM
dpc-4512	56	6	.	.	PUNCT
dpc-4512	57	1	petrelli	petrelli	PROPN
dpc-4512	57	2	f	f	PROPN
dpc-4512	57	3	,	,	PUNCT
dpc-4512	57	4	giannini	giannini	PROPN
dpc-4512	57	5	d	d	PROPN
dpc-4512	57	6	,	,	PUNCT
dpc-4512	57	7	bilia	bilia	PROPN
dpc-4512	57	8	s	s	PART
dpc-4512	57	9	,	,	PUNCT
dpc-4512	57	10	et	et	PROPN
dpc-4512	57	11	al	al	PROPN
dpc-4512	57	12	.	.	PROPN
dpc-4512	57	13	efficacy	efficacy	NOUN
dpc-4512	57	14	and	and	CCONJ
dpc-4512	57	15	safety	safety	NOUN
dpc-4512	57	16	of	of	ADP
dpc-4512	57	17	omalizumab	omalizumab	NOUN
dpc-4512	57	18	therapy	therapy	NOUN
dpc-4512	57	19	in	in	ADP
dpc-4512	57	20	urticaria	urticaria	NOUN
dpc-4512	57	21	vasculitis	vasculitis	PROPN
dpc-4512	57	22	.	.	PUNCT
dpc-4512	57	23	  	  	SPACE
dpc-4512	58	1	front	front	ADJ
dpc-4512	58	2	allergy	allergy	NOUN
dpc-4512	58	3	.	.	PUNCT
dpc-4512	59	1	2022;3:952079	2022;3:952079	PROPN
dpc-4512	59	2	.	.	PUNCT
dpc-4512	59	3	doi:10.3389	doi:10.3389	PROPN
dpc-4512	59	4	/	/	SYM
dpc-4512	59	5	falgy.2022.952079	falgy.2022.952079	NOUN
dpc-4512	59	6	figure	figure	NOUN
dpc-4512	59	7	1	1	NUM
dpc-4512	59	8	.	.	PUNCT
dpc-4512	59	9	widespread	widespread	ADJ
dpc-4512	59	10	annular	annular	ADJ
dpc-4512	59	11	erythematous	erythematous	ADJ
dpc-4512	59	12	urticarial	urticarial	ADJ
dpc-4512	59	13	plaques	plaque	NOUN
dpc-4512	59	14	and	and	CCONJ
dpc-4512	59	15	hyperpigmentation	hyperpigmentation	NOUN
dpc-4512	59	16	on	on	ADP
dpc-4512	59	17	the	the	DET
dpc-4512	59	18	(	(	PUNCT
dpc-4512	59	19	a	a	PRON
dpc-4512	59	20	)	)	PUNCT
dpc-4512	59	21	trunk	trunk	NOUN
dpc-4512	59	22	,	,	PUNCT
dpc-4512	59	23	(	(	PUNCT
dpc-4512	59	24	b	b	NOUN
dpc-4512	59	25	)	)	PUNCT
dpc-4512	59	26	face	face	NOUN
dpc-4512	59	27	,	,	PUNCT
dpc-4512	59	28	and	and	CCONJ
dpc-4512	59	29	(	(	PUNCT
dpc-4512	59	30	c	c	NOUN
dpc-4512	59	31	)	)	PUNCT
dpc-4512	59	32	leg	leg	NOUN
dpc-4512	59	33	.	.	PUNCT